# Shield Therapeutics: Reassessing the US opportunity

- Link: https://www.directorstalkinterviews.com/shield-therapeutics-reassessing-the-us-opportunity/412963784
- Published: 2021-01-06T10:06:00+00:00
- Author: Amilia Stone

**Shield Therapeutics plc **(LON:STX) is a commercial-stage company delivering specialty
products that address patients’ unmet medical needs, with an initial focus on treating
iron deficiency (ID). Feraccru®/Accrufer® has been approved by the regulators in
both Europe and the US. For various reasons, STX has been unable to secure a commercial
partner for Accrufer in the US. Consequently, the board is now considering an STX-
led launch option, thereby retaining all the US profits. Financial modelling shows
the logic of this option, but it would necessitate financing the working capital
requirements covering the next two years in the region of £25m-£30m.

 * **Strategy:** STX’s strategy has been to out-license commercialisation rights
   to partners with appropriate expertise in target markets. Although this strategy
   has been successful in Europe and China, the company has not been able to secure
   a satisfactory deal for the US, which has necessitated a re-think.
 * **US options:** During multiple US commercialisation discussions, potential partners
   have shared with STX management considerable intelligence about the US sales 
   and marketing opportunity for Accrufer. Based on this information and its own
   research, the board has concluded that STX could launch Accrufer by itself.
 * **Financial implications:** Financial modelling suggests that retention of the
   commercialisation rights and profits to Accrufer in the US results in substantially
   higher returns for shareholders. However, to achieve this, the company will need
   additional working capital of £25m-£30m for the next two years.
 * **Risks:** Operationally, the main risk is that of execution, with little in-
   house commercial experience; however, STX has begun to address this by recruiting
   experienced US commercial managers. Finance will also be required, potentially
   through a combination of specialist debt and equity.
 * **Investment summary:** Subject to financing being available, the Shield Therapeutics-
   led option for Accrufer appears to be the best option for shareholders. The attributes
   and positioning off Accrufer are well-suited to the COVID-19 environment, eliminating
   the hospital attendance risk. The shares have over-reacted to the “lack of deal”
   news and should recover quickly once the uncertainty is removed.

[DOWNLOAD THE FULL REPORT](https://www.hardmanandco.com/research/corporate-research/reassessing-the-us-opportunity/#report-download)

Share on:
